Menzies-Gow A, Corren J, Bourdin A, et al. - Researchers conducted this phase 3, multicenter, randomized, double-blind, placebo-controlled trial to assess tezepelumab’s (a human monoclonal antibody) efficacy as well as safety in patients suffering from severe, uncontrolled asthma. They randomized patients (n = 1061; 12 to 80 years of age) to receive tezepelumab (210 mg) or placebo subcutaneously every 4 weeks for 52 weeks. Findings revealed fewer exacerbations and better lung function, asthma control, and health-related quality of life in relation to treatment with tezepelumab, vs placebo, in patients suffering from severe, uncontrolled asthma.